{
      "ptx_code": "PTX003",
      "chem_name": "[4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid",
      "casrn": "50892-23-4",
      "dtxsid": "DTXSID4020290",
      "smiles": "CC1=C(C)C(NC2=NC(SCC(O)=O)=NC(Cl)=C2)=CC=C1",
      "inchikey": "SZRPDCCEHVWOJX-UHFFFAOYSA-N",
      "label": "PTX003 | [4-Chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid",
      "drugbank_id": "",
      "use_class": "Pharmaceutical",
      "tox_class": "Cardiotoxicity; Genotoxicity; Nephrotoxicity; Hepatotoxicity; Neurotoxicity",
      "chem_name_user": "WY-14643 / Pirinixic acid",
      "mw_g_mol": "323.80",
      "solubility_h2o_mol_liter": "0.15",
      "source_solubility_h2o": "est., EPISUITE",
      "henry_coefficient_atm_m3_mol": "1.42e-10",
      "source_henry": "est., EPISUITE (Bond)",
      "log_kaw_kh_rt": "8.24",
      "source_kaw": "Comptox",
      "pka_acid": "2.80",
      "pka_base": "4.98",
      "source_pka": "ACD pKa/GALAS",
      "log_kow_liter_liter": "4.02",
      "source_kow": "mean of ACD consensus and KOWWIN",
      "log_dlipw_ph74_liter_liter": "3.20",
      "source_dlipw": "Kow-QSAR (?mw=1)",
      "freely_dissolved_fraction": "0.11",
      "density_kg_liter": "",
      "source_density": "",
      "average_mass": "323.80",
      "boiling_point": "",
      "source_boiling_point": "",
      "melting_point": "155.0 \u00b0C",
      "source_melting_point": "Tokyo Chemical Industry (Chemical company)",
      "vapor_pressure": "",
      "source_vapor_pressure": "",
      "baseline_drerio": "114.00",
      "baseline_dmagna": "81.50",
      "baseline_celegans": "179.18",
      "baseline_xlaevis": "86.33",
      "baseline_dmelanogaster": "702.81",
      "baseline_cells": "1.45e-04",
      "baseline_cells_generic_micromole_liter_free_ec10": "1.66e-05",
      "moa_drugbank": "",
      "protein_binding": "",
      "moa_t3db": "",
      "aop": [
            {
                  "AOP_id": 6,
                  "AOP_name": "Antagonist binding to PPAR\u03b1 leading to body-weight loss "
            },
            {
                  "AOP_id": 18,
                  "AOP_name": "PPAR\u03b1 activation in utero leading to impaired fertility in males "
            },
            {
                  "AOP_id": 19,
                  "AOP_name": "Androgen receptor antagonism leading to adverse effects in the male foetus (mammals) "
            },
            {
                  "AOP_id": 34,
                  "AOP_name": "LXR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 36,
                  "AOP_name": "Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis "
            },
            {
                  "AOP_id": 57,
                  "AOP_name": "AhR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 58,
                  "AOP_name": "NR1I3 (CAR) suppression leading to hepatic steatosis "
            },
            {
                  "AOP_id": 61,
                  "AOP_name": "NFE2L2/FXR activation leading to hepatic steatosis "
            },
            {
                  "AOP_id": 72,
                  "AOP_name": "Epigenetic modification of PPARG leading to adipogenesis "
            },
            {
                  "AOP_id": 97,
                  "AOP_name": "5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline "
            },
            {
                  "AOP_id": 98,
                  "AOP_name": "5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation "
            },
            {
                  "AOP_id": 123,
                  "AOP_name": "Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription "
            },
            {
                  "AOP_id": 131,
                  "AOP_name": "Aryl hydrocarbon receptor activation leading to uroporphyria "
            },
            {
                  "AOP_id": 154,
                  "AOP_name": "Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response "
            },
            {
                  "AOP_id": 167,
                  "AOP_name": "Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. "
            },
            {
                  "AOP_id": 187,
                  "AOP_name": "Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage "
            },
            {
                  "AOP_id": 195,
                  "AOP_name": "5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase "
            },
            {
                  "AOP_id": 200,
                  "AOP_name": "Estrogen receptor activation leading to breast cancer   "
            },
            {
                  "AOP_id": 203,
                  "AOP_name": "5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline "
            },
            {
                  "AOP_id": 204,
                  "AOP_name": "5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase "
            },
            {
                  "AOP_id": 318,
                  "AOP_name": "Glucocorticoid Receptor activation leading to hepatic steatosis "
            }
      ],
      "targets": []
}